Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Shuang, Shen, Meng-Zhu, Zhang, Xiao-Hui, Xu, Lan-Ping, Wang, Yu, Yan, Chen-Hua, Chen, Huan, Chen, Yu-Hong, Han, Wei, Wang, Feng-Rong, Wang, Jing-Zhi, Zhao, Xiao-Su, Qin, Ya-Zhen, Chang, Ying-Jun, Liu, Kai-Yan, Huang, Xiao-Jun, Mo, Xiao-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770808/
https://www.ncbi.nlm.nih.gov/pubmed/35070977
http://dx.doi.org/10.3389/fonc.2021.773394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770808/
https://www.ncbi.nlm.nih.gov/pubmed/35070977
http://dx.doi.org/10.3389/fonc.2021.773394

Ejemplares similares